202 related articles for article (PubMed ID: 31437546)
41. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
42. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
[TBL] [Abstract][Full Text] [Related]
43. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
44. Immune checkpoint inhibitors-related orchitis.
Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
[No Abstract] [Full Text] [Related]
45. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
Afzal MZ; Shirai K
J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
[TBL] [Abstract][Full Text] [Related]
46. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
47. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
[No Abstract] [Full Text] [Related]
48. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
49. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
50. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
51. [Histoseminar on inflammatory bowel diseases (IBD): Case n
Fléjou JF
Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
[No Abstract] [Full Text] [Related]
52. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
53. Diplopia and Acute Vision Loss After Nivolumab Plus Ipilimumab Therapy.
Tambe A; Basnet A; Tambe V; Badrinath M; Mandru R
Am J Ther; 2020 Sep; 28(2):e246-e247. PubMed ID: 33687029
[No Abstract] [Full Text] [Related]
54. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
55. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
56. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
57. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
Kosche C; Owen JL; Choi JN
Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
[TBL] [Abstract][Full Text] [Related]
58. Autologous graft-versus-host disease with combined immune checkpoint blockade.
Kofler L; Dréno B; Röcken M
Eur J Cancer; 2018 Sep; 101():275-277. PubMed ID: 30017386
[No Abstract] [Full Text] [Related]
59. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
60. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
